Healthcare professionals have chosen Lantus® for over 18 years1
DEMONSTRATED LONG-TERM CV SAFETY DATA IN THE LANDMARK ORIGIN TRIAL1-3*
*Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure.
CV Evaluation from the ORIGIN Trial over 6.2 Years (N=12,537)
- Metformin was used by 47% of the insulin-glargine group and 60% of the standard-care group which may have been cardioprotective.
- The trial involved people who were not normally prescribed insulin and in whom insulin glargine was used to achieve fasting plasma glucose levels much lower than those typically achieved with insulin therapy. However, the effect in participants with and those without diabetes was similar.
- The trial was designed to test the effect of using titrated basal insulin to control glucose levels vs standard-care with guideline-suggested degrees of glycemic control; the trial was specifically not designed to test more intense vs less intense glucose lowering.
No statistically significant differences between Lantus® and standard care in the co-primary endpoints
- Similar results were observed between Lantus® and standard care for all cause mortality
Mean A1C over 6.2 years (median)
A randomized study of patients with IFG and/or IGT or early type 2 diabetes mellitus and established CV disease or CV risk at baseline. Patients received either Lantus® (n=6264) titrated to a target FPG of ≤95 mg/dL or standard care (n=6273). Standard care patients remained on their original treatment, if applicable, at randomization. Additional agents could be added as needed at the discretion of the investigator. The co-primary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. Median follow-up: 6.2 years.
Lantus® Savings Offers
Commercially insured patients pay as low as $0 and no more than $99* for a 30-day supply. For patients without insurance there is an offer too.Terms and Eligibility Restrictions Apply.See Below*
Lantus is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus should be administered once a day at the same time every day.
Limitations of Use: Lantus is not recommended for the treatment of diabetic ketoacidosis.
Important Safety Information for Lantus®
Important Safety Information for Lantus®
Lantus is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or one of its excipients.
Monitor blood glucose in all patients treated with insulin. Modify insulin regimen only under medical supervision. Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.
Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.
Do not dilute or mix Lantus with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus via an insulin pump or intravenously because severe hypoglycemia can occur.
Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus, and may be life-threatening.
Medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Patients should be instructed to always verify the insulin label before each injection.
Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus, treat and monitor until symptoms resolve.
A reduction in the Lantus dose may be required in patients with renal or hepatic impairment.
As with all insulins, Lantus use can lead to life-threatening hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.
Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.
Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).
Adverse reactions commonly associated with Lantus include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.
Lantus SoloSTAR is a disposable single-patient-use prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen: otherwise they may not get the correct amount of insulin, which may affect their blood glucose.
*Eligibility Restrictions & Offer Terms:
Insulins Valyou Savings Program: Sanofi insulins included in this program are: ADMELOG® (insulin lispro injection) 100 Units/mL, TOUJEO® SoloStar® (insulin glargine injection) 300 Units/mL, TOUJEO® Max SoloStar® (insulin glargine injection) 300 Units/mL, LANTUS® (insulin glargine injection) 100 Units/mL, INSULIN GLARGINE injection 100 Units/mL (U-100) and APIDRA® (insulin glulisine injection) 100 Units/mL.
Sanofi US Copay Program: This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: The Federal Employees Health Benefits (FEHB) Program is not a federal or state government healthcare program for purposes of the savings program. Void where prohibited by law.
Lantus or Insulin Glargine U-100 (Winthrop): Pay as low as $0 up to $99 for a 30-day supply. Amount depends on insurance coverage. Valid up to 10 packs per fill; offer valid for 1 fill every thirty days.
Savings may vary depending on patients' out-of-pocket costs. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke or amend these programs without notice.
1. Lantus® Prescribing Information.
2. ORIGIN Trial Investigators. Am Heart J. 2008;155(1):26-32.
3. ORIGIN Trial Investigators. N Engl J Med. 2012;367(4):319-328.
All registered trademarks cited are property of their respective owners.